Publications

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.

JIT, M; Demarteau, N; Elbasha, E; Ginsberg, G; Kim, J; Praditsitthikorn, N; Sinanovic, E; Hutubessy, R;

2011

BMC medicine, (2011).9 1 10.1186/1741-7015-9-54.

Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective.

Beck, CR; McKenzie, BC; Hashim, AB; HARRIS, RC; Zanuzdana, A; Agboado, G; Orton, E; Béchard-Evans, L; Morgan, G; Stevenson, C; Weston, R; Mukaigawara, M; Enstone, J; Augustine, G; Butt, M; Kim, S; Puleston, R; Dabke, G; Howard, R; O'Boyle, J; O'Brien, M; Ahyow, L; Denness, H; Farmer, S; Figureroa, J; ... Nguyen-Van-Tam, JS.

2011

PloS one, (2011).6 12 10.1371/journal.pone.0029249.

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

RTS,S Clinical Trials Partnership,; Agnandji, ST; Lell, B; Soulanoudjingar, SS; Fernandes, JF; Abossolo, BP; Conzelmann, C; Methogo, BG N O; Doucka, Y; Flamen, A; Mordmüller, B; Issifou, S; Kremsner, PG; Sacarlal, J; Aide, P; Lanaspa, M; Aponte, JJ; Nhamuave, A; Quelhas, D; Bassat, Q; Mandjate, S; Macete, E; Alonso, P; Abdulla, S; Salim, N; ... Vansadia, P.

2011

The New England journal of medicine, (2011).365 20 10.1056/NEJMoa1102287.

Response to comment on article by Jit et al. 'The cost effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe'.

JIT, M; Bilcke, J; Mangen, M-JJ; Salo, H; Melliez, H; EDMUNDS, WJ; Yazdanpanah, Y; Beutels, P;

2011

Vaccine, (2011).29 21 10.1016/j.vaccine.2011.02.104.

Effectiveness of trivalent and pandemic influenza vaccines in England and Wales 2008-2010: results from a cohort study in general practice.

Hardelid, P; Fleming, DM; Andrews, N; Barley, M; Durnall, H; MANGTANI, P; Pebody, R;

2011

Vaccine, (2011).30 7 10.1016/j.vaccine.2011.12.038.

7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?.

Choi, YH; JIT, M; Gay, N; Andrews, N; Waight, PA; Melegaro, A; George, R; MILLER, E;

2011

PloS one, (2011).6 10 10.1371/journal.pone.0026190.

Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths.

ALEXANDER, N; CUNDILL, B; Sabatelli, L; Bethony, JM; Diemert, D; Hotez, P; SMITH, PG; RODRIGUES, LC; BROOKER, S;

2011

Vaccine, (2011).29 20 10.1016/j.vaccine.2011.03.026.

Effect of pneumococcal vaccination on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Fijian children.

Dunne, EM; Manning, J; Russell, FM; Robins-Browne, RM; MULHOLLAND, EK; Satzke, C;

2011

Journal of clinical microbiology, (2011).50 3 10.1128/JCM.06589-11.

Accelerating vaccine development and deployment: report of a Royal Society satellite meeting.

Bregu, M; Draper, SJ; Hill, AV S; GREENWOOD, BM;

2011

Philosophical transactions of the Royal Society of London Series B, Biological sciences, (2011).366 1579 10.1098/rstb.2011.0100.

Pneumococcal glycoconjugate vaccines produce antibody responses that strongly correlate with function.

Licciardi, PV; Balloch, A; Russell, FM; Nahm, MH; MULHOLLAND, K; Tang, ML K;

2011

Nature reviews Drug discovery, (2011).10 5 10.1038/nrd3012-c1.